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Response to treatment with
Tumor Treating Fields varies
among glioblastoma patients.
The field strength induced
within the tumor is a crucial
determinant for effective
reduction in tumor growth.
This computational study
shows how the field delivery
to the tumor can be opti-
mized by specifically placing
the transducer arrays in close
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http://dx.doi.org/10.1016/j.ijrobp.2015.11.042Purpose: To investigate tumors of different size, shape, and location and the effect of
varying transducer layouts on Tumor Treating Fields (TTFields) distribution in an
anisotropic model.
Methods and Materials: A realistic human head model was generated from MR im-
ages of 1 healthy subject. Four different virtual tumors were placed at separate loca-
tions. The transducer arrays were modeled to mimic the TTFields-delivering
commercial device. For each tumor location, varying array layouts were tested. The
finite element method was used to calculate the electric field distribution, taking into
account tissue heterogeneity and anisotropy.
Results: In all tumors, the average electric field induced by either of the 2 perpendic-
ular array layouts exceeded the 1-V/cm therapeutic threshold value for TTFields effec-
tiveness. Field strength within a tumor did not correlate with its size and shape but was
higher in more superficial tumors. Additionally, it always increased when the array
was adapted to the tumor’s location. Compared with a default layout, the largest in-
crease in field strength was 184%, and the highest average field strength induced in
a tumor was 2.21 V/cm.
Conclusions: These results suggest that adapting array layouts to specific tumor loca-
tions can significantly increase field strength within the tumor. Our findings support
the idea of personalized treatment planning to increase TTFields efficacy for patients
with GBM. 2016 TheAuthors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hn, Institute of Biophysics
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Tumor Treating Fields (TTFields) are a novel antimitotic
cancer treatment modality that disrupts cancer cell repli-
cation by applying alternating electric fields of low
intensity (1-3 V/cm) and intermediate frequencies (100-
300 kHz). The biological effects of TTFields were first
observed during in vitro experiments, which showed a
prolonged or completely arrested mitotic phase of treated
cancer cells accompanied by membrane blebbing and
rupture, often leading to cell death (1). The effect of
TTFields is frequency-dependent; each cell line has a
specific optimal frequency with maximal inhibitory effect
on cell division (eg, 200 kHz for glioma cells) (2). TTFields
are also dose-dependent; that is, the inhibitory effect of
TTFields starts at 1 V/cm and increases with increasing
field intensity (1, 2). After the antitumor effect of TTFields
was demonstrated in animal tumor models (2), the Optune
device (Novocure, Haifa, Israel), formerly known as the
NovoTTF-100A system, was developed to deliver TTFields
in human subjects with glioblastoma multiforme (GBM).
In vitro experiments further showed that 2 perpendicular
field directions were approximately 20% more effective
than a single direction (2). Thus, clinically, TTFields are
applied continuously by 2 pairs of transducer arrays, which
are sequentially switched. Both pairs are placed on the
patient’s shaved scalp, one to the left and right (LR) of the
tumor and one anterior and posterior (AP) to it (Fig. 1).
After encouraging results of a pilot trial in patients with
recurrent GBM (2) indicating a favorable safety profile, a
phase 3 trial (EF-11) compared TTFields therapy with
physician’s choice chemotherapy. The results showed
similar efficacy between the 2 study arms, with no drugdefault
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Fig. 1. Head model with scalp surface and ventricles. Tumors
layouts. Default and symmetric pads displayed in red/blue and a
more details.toxicity and better quality of life in TTFields-treated pa-
tients (3). Subsequently, the Patient Registry Dataset study
(4), including 457 patients with recurrent GBM treated with
Optune, showed significantly longer median overall sur-
vival with TTFields therapy in clinical practice
(9.6 months) than in the EF-11 trial (6.6 months) and
greater 1- and 2-year overall survival rates (1 year: 44% vs
20%; 2 years: 30% vs 9%). A recent phase 3 EF-14 trial
comparing the combination of TTFields with temozolo-
mide versus temozolomide alone in newly diagnosed GBM
was terminated during interim analysis owing to early
success of temozolomide with TTFields (5).
In all studies, response variability among patients was
observed, which might be related to the efficacy of
TTFields therapy being dose dependent. Because the field
intensity cannot be measured inside the human head,
computational modeling can be used as a proxy to estimate
the induced electric field distribution. Previous studies
showed that the field distribution is different for LR and AP
pairs, and nonuniform, owing to tissue heterogeneity, with
approximately 60% of the brain exposed to a field greater
than 1 V/cm (6, 7). Furthermore, the average field in a
virtual tumor at the same location in 2 different subjects
showed 25% variation about the mean value (8). This last
study incorporated anisotropic conductivity tensors esti-
mated using diffusion tensor imaging (DTI) data (9),
because including white matter anisotropy was shown to
substantially affect the electric field distribution in related
techniques (10-13). Nonetheless, when including anisot-
ropy for TTFields calculations, the field in the brain
remained almost unchanged, and the average field strength
in the tumor increased by 10% or less (8). A sensitivity
analysis with reported ranges of conductivity and permit-
tivity of head tissues showed a variation in field strength oft4
asymmetrical t4 symmetrical t4 asymmetrical
t1-t4 are presented in green. Top and front view of different
symmetric ones in yellow/green (insets). See main text for
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studies, only 1 tumor location and a single array layout
were examined.
In this study we investigated tumors of different size,
shape, and location and the effect of varying transducer
layouts on TTFields distribution in an anisotropic model.
We compared 2 spherical virtual tumors of equal size at
different locations. Two larger, irregularly shaped tumors
were also investigated. For the new tumor locations, we
proposed adapted transducer layouts to improve field de-
livery to the tumor.Methods and Materials
Creating the model
A realistic human head model was derived from MRI data
of a healthy, young female subject, which consisted of T1
and T2 images with 1  1  1-mm3 resolution. The MR
images were segmented into scalp, skull, cerebrospinal
fluid, gray matter (GM; including the cerebellum), white
matter (WM), and ventricles. After registering the images
to Montreal Neurological Institute space with FSL (14), the
SimNibs pipeline (15) and the software package Brainsuite
(16) were used to obtain each tissue surface.
The 4 virtual tumors were modeled within Mimics
(Materialise, Leuven, Belgium) (Fig. 1). All consisted of a
necrotic core and an active tumor shell with different
dielectric properties (Table 1). As previously described (6)
spherical tumor, t1, was placed in the right hemisphere near
a lateral ventricle. The second tumor, t2, was an equally
sized sphere, but shifted to a more anterior and inferior
location. Both tumors t1 and t2 were represented by 2
concentric spheres, with core and shell volumes of 1.4 cm3
and 2.8 cm3, respectively. Two irregularly shaped tumors,
t3 and t4, were also created. Tumor t3 was placed in the left
anterior cingulate cortex, extending into the prefrontal
cortex, with a shell volume of 13.9 cm3 and a core volume
of 2.8 cm3. Tumor t4 was larger, with a shell volume ofTable 1 Dielectric tissue properties at 200 kHz
Parameter
Conductivity,
s (S/m)
Relative
permittivity, εr
Head
Scalp 0.25 5000
Skull 0.013 200
Cerebrospinal fluid 1.79 110
Gray matter 0.25 3000
White matter 0.12 2000
Tumor
Shell 0.24 2000
Core 1.00 110
Array
Gel 0.10 100
Transducer 0 10,00022.8 cm3 and a core volume of 3.8 cm3, and was also placed
in the left hemisphere, but more superficial and in the
posterior frontal lobe, reaching the parietal lobe.
Each transducer array consisted of 3  3 transducers
separated by 22 mm in one dimension and 33 mm in the
other, representing the Optune system. A thin gel layer
(0.5-2 mm) of 10-mm diameter was placed underneath each
transducer, consisting of a 1-mm-thick ceramic disc, 9 mm
in diameter. The default layout represents a symmetric
configuration of LR and AP arrays (Fig. 1, left). This layout
was applied to all tumors. For tumor locations other than
for central t1, the array layouts were adapted to place them
as close as possible to the tumor, taking into account space
constraints. A second layout was created for t2, and 2 more
were created for t3 and t4 (Fig. 1). For t3, only the back
array of the AP setup differs between the 2 layouts: the
asymmetric one is indicated by the yellow and green discs
and the symmetric one by the blue and red discs (insets in
Fig. 1). For t4, the right array of the LR pair was adapted to
model a second asymmetric layout. Mimics was used to
assemble all surface meshes into a volume mesh.
Solving the model
The electric field distribution within the brain was calcu-
lated using the finite element method to solve the quasi-
static approximation of the Maxwell’s equations, which is
valid for this model (17). We used the Electric Currents
Interface of COMSOL Multiphysics simulation software,
which solves a current conservation problem for the scalar
electric potential V. The chosen boundary conditions as-
sume continuity of the normal component of the current
density in all interior boundaries and electric insulation at
the external boundaries. At each active transducer, a vari-
able electrical potential was set at that boundary so that the
integral of the current density normal to it is equal to
100 mA. The values of the heterogeneous dielectric prop-
erties were estimated specifically for 200 kHz, following a
previous study (6) (Table 1).
The FSL diffusion toolbox (18) was used to correct and
register the DTI images and calculate the eigenvectors,
eigenvalues, and fractional anisotropy. Subsequently, the
SimNibs MATLAB scripts (15) were used to estimate the
conductivity tensors with baseline conductivity of the WM
and the GM (Table 1). We used the volume normalized
approach (19), whereby the geometric means of the ei-
genvalues of the conductivity tensor in each voxel are
matched locally to isotropic reference values.
Results
All tumors and transducer layouts were evaluated. The
average electric field strength was calculated in the brain,
tumor shell (Table 2), and core. For tumor shells t2-t4, the
values always increased for adapted array layouts (Table 2).
In the necrotic core, the average field was always lower
Table 2 Average electric field strengths (V/cm) in all tumor shells for different array layouts
Tumor
LR AP
Default sym asym Max (sym, asym) default Default sym asym max(sym,asym)/default
t1 1.68 1.15
t2 1.10 2.03 184% 2.08 2.21 107%
t3 1.10 1.76 1.76 161% 1.75 1.94 1.95 111%
t4 1.56 2.03 2.03 131% 1.20 1.46 1.61 134%
Abbreviations: AP Z anterior-posterior; asym Z asymmetric; LR Z left-right; sym Z symmetric.
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direction, the ratio between average field in the shell and
core was similar for all layouts.
The percentage of the tumor shell’s volume having a
field strength higher than 1, 2, or 3 V/cm was calculated.
These above-threshold volumes (ATVs) will be referred to
as ATV1, ATV2, and ATV3, respectively. The ATVs also
increased for adapted array layouts (Table 3). The ATVs
were evaluated separately for LR and AP setups, and for
combined treatment (ie, the values in the LR*AP column of
Table 3 represent the tumor shell’s volume with a field
strength above a certain value in both setups). Only
maximum ATV values are presented, which for tumors t2-
t4 originated from the adapted layouts. For tumors t3 and
t4, the highest ATVs were achieved either for the sym-
metric or asymmetric layout, as noted in Table 3. The in-
crease of ATVs compared with the values obtained with the
default layout varied among tumors and setups (values in
parentheses in Table 3). The highest increase of 48 per-
centage points was observed for the ATV2 of t2 under LR
stimulation. In this case, the default layout induced a field
greater than 2 V/cm in only 1% of the tumor shell, whereas
for the adapted LR arrays, the ATV2 was 49%.
Figure 2 shows a comparison of the electric field dis-
tribution in axial slices through t3 induced by the default
(middle) and the symmetric layout (bottom). The field is
displayed only in the GM, WM, and tumor. The default LR
setup was too central to have a strong effect on the frontal
tumor (ie, the field was highest near the posterior limb of
the internal capsule, close to the occipital horn of the lateralTable 3 Largest ATVs in all tumor shells for LR and AP setups se
Tumor
ATV1
LR AP LR*AP LR
t1 90% 58% 53% 23%
t2 99%
(þ41%)*
100%
(þ0%)*
97%
(þ43%)*
49%
(þ48%)*
t3 99%
(þ43%)y
100%
(þ1%)y
98%
(þ44%)y
25%
(þ24%)y
t4 100%
(þ3%)y
100%
(þ11%)*
100%
(þ14%)*
51%
(þ38%)y
Abbreviation: ATV Z above-threshold volume. Other abbreviations as in T
The increase in percentage points compared with the default layout is given
* Values originated from the asymmetric layout.
y Values originated from the symmetric layout.ventricle). When the LR array was adapted, the “hotspots”
were shifted to the anterior limb of the internal capsule,
close to the frontal horn of the lateral ventricle, resulting in
additional hotspots at the interface with the tumor. The
tumor’s proximity to the anterior array induced high
average fields within the tumor shell for default and
adapted AP setups (Table 2). The strongest field appeared at
the interface with the tumor, in the frontal forceps, and in
the genu of the corpus callosum.
In the largest tumor, t4, the default layout produced
average field strengths comparable to those in t1 (Table 2).
However, by raising the transducer arrays closer to the
higher tumor location, field strengths were increased, and
hotspots were shifted from the temporal to the parietal lobe.
Figure 3 illustrates the difference in the induced field dis-
tribution in t4 when the asymmetric layout is used instead
of the default one. The stronger field produced by the
asymmetric layout in the higher regions of the brain in the
genu of internal capsule was clearly visible in the coronal
and sagittal slices.Discussion
In this study we examined tumors of different shape, size,
and location, and we investigate whether array placement
may influence TTFields efficacy. Tumor shape and size, up
to 26.6 cm3 total volume, did not have a noticeable impact
on the average electric field strength in the tumor shell,
owing primarily to the large size of the individual arrays.parately and for combined treatment (LR*AP)
ATV2 ATV3
AP LR*AP LR AP LR*AP
2% 0% 4% 0% 0%
50%
(þ5%)*
22%
(þ21%)*
8%
(þ8%)*
17%
(þ5%)*
0%
(þ0%)*
36%
(þ14%)*
6%
(þ6%)*
1%
(þ1%)*
4%
(þ3%)y
0%
(þ0%)y
8%
(þ7%)*
2%
(þ2%)*
2%
(þ2%)y
0%
(þ0%)*
0%
(þ0%)y
able 2.
in parentheses.
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Fig. 2. Electric field distribution in 2 axial slices through t3 (contour shown in the left hemisphere, anteriorly). Default and
symmetric layouts are presented for left-right (LR) and anterior-posterior (AP) setups. Corresponding anatomic slices and
their position in the head model are presented at the top.
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layouts, quantifying the difference in the average field
strength within the tumor, and determining whether the
ATVs can be enlarged.
The NovoTal system (Novocure) is approved in the
United States to produce a personalized transducer array
layout to maximize the intensity of TTFields within the
tumor on the basis of morphologic measurements of the
head, tumor size, and location(s) (20). Our assumptions for
placing the adapted arrays are similar, because they were
placed as close as possible to the tumor, taking into account
space and anatomic constraints. Because this method does
not yield one single layout, 2 possible layouts were
compared for the irregular tumors. The results predict that
by adapting the layout, the average field strength in the
tumor would always increase. Yet, this increase varies: the
smallest increase of 107% was present for t2 with the AP
array, whereas the largest increase of 184% was predicted
also for t2, but under LR stimulation (Table 2). Nonethe-
less, for all array configurations, including the default, the
average field strength within all tumor shells exceeded the
therapeutic threshold of 1 V/cm (Table 2). The highest
average field of 2.21 V/cm appeared in the shell of t2 under
adapted AP stimulation (Table 2). Apart from this
maximum, the average field strength in the shell seemed tobe close to or higher than 2 V/cm in many cases (eg, t2 with
adapted LR arrays, t3 with adapted AP arrays, and t4 with
adapted LR arrays). This increased field strength is crucial
for treatment efficacy, because in vitro experiments predict
a significant reduction in treated cell number when the field
intensity is raised from 1 to 2 V/cm (1, 2) (eg, for rat gli-
oma cells complete proliferation arrest has been seen after a
24-hour exposure to TTFields of 2.25 V/cm [1]).
For tumors t3 and t4, the increases for the symmetric and
asymmetric setups were quite similar. Only for the AP
stimulation of t4 was there a noticeable difference between
the 2 adapted layouts, from 1.46 to 1.61 V/cm in the shell.
These results indicate that the location of some arrays could
be changed during treatment without losing efficacy. This
might be of interest for the 16% of patients (3) who showed
mild-to-moderate contact dermatitis underneath the
transducers.
Depending on tumor location, either the LR or the AP
array is more effective. Our findings suggest that for tumors
located close to the central coronal plane, the LR setup
produces stronger fields, whereas for tumors that are either
more anterior or posterior, the AP setup is more effective.
Efficacy is also characterized by the evaluated ATVs.
The ATV1 values correspond to the percentage of tumor
shell exposed to fields higher than the therapeutic threshold
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Fig. 3. Electric field distribution in a coronal and a sagittal slice through t4 (contour shown in the left hemisphere, above
the ventricles). Default and asymmetric layouts are presented for left-right (LR) and anterior-posterior (AP) setups. Corre-
sponding anatomic slices and their position in the head model are presented at the top.
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90% for the LR array, it was reduced to 58% for the AP
array, and only 53% for combined treatment. Thus, this
central tumor is the most difficult to treat, where an adap-
tion of the default layout, which cannot be placed closer to
the tumor, will not lead to improvement. In all other tu-
mors, the adapted layouts led to >97% exposure of the
tumor shell to fields higher than 1 V/cm for combined
treatment. Results show that TTFields may be most effec-
tive for t2: ATV2 values for both arrays were approximately
50% and 22% for LR*AP, and the ATV3 for the adapted
AP arrays is 17%. The increased efficacy of TTFields by
adapting layouts is shown in Table 3. Some ATVs are more
than 40% higher when compared with the default layout
(eg, the ATV1 induced by the LR array and LR*AP of
tumors t2 and t3 and the ATV2 of t2 for the LR array).
Furthermore, only for the adapted layouts the ATV2 values
for combined treatment are nonzero for all tumors.
For the default layout the average electric fields in the
brain were ELR Z 1.45 V/cm and EAP Z 1.48 V/cm.
Despite the fact that these values and corresponding spe-
cific absorption rates are quite high, only limited adverse
effects were reported in TTFields patients, as discussed in
more detail elsewhere (6, 8). In all other array layouts, the
average field strengths in the brain were lower. The lowest
average field within the brain of 1.22 V/cm was induced by
the adapted LR array for t2 and in the AP arrays of both
adapted layouts for t4. Thus, apart from increasing the field
within the tumor, adapting layouts decreases the fieldexposure of healthy tissues. This could also be the reason
for the “out-of-field” recurrences observed in a recent study
involving GBM patients treated with TTFields (21). In their
report, the authors assumed that when the field is optimized
in one direction, the field strength decreases elsewhere,
where newly seeded tumor cells would be able to divide.
The specific field distribution induced in the brain for t3
showed much lower field strength in the parietal area,
which would correlate with recurrences observed in 2 pa-
tients in their study. The authors concluded that adjustment
of arrays may lead to better response for locally progressing
tumors. For multifocal diseases it might be justified to cycle
through different layouts during earlier stages of treatment.
In summary, computational modeling is a practical
means to analyze induced field distribution during TTFields
treatment and to investigate factors that influence the field
strength in the tumor. Previous studies focused on
analyzing effects of including anisotropy of the WM,
changing dielectric tissue properties and on intersubject
variability (8). One limitation of all models, including the
one presented here, is that local changes in tumor con-
ductivity that might seem to be due to morphologic alter-
ations, such as cell blebbing and rupture, are not accounted
for. Indeed, it has been shown that the conductivity of the
tumor has the strongest influence on the electric field in the
tumor itself (8). An uncertainty in predicted average fields
in the tumor shell of approximately 33% was evaluated
for conductivity values reported in literature. As already
proposed (8), one way to address this limitation is to
Volume 94  Number 5  2016 Improving TTFields efficacy in GBM 1143acquire MRI and DTI data in patients. This additional in-
formation about the conductivity of tumor tissues and
edematous areas can then be incorporated into realistic
computational head models of patients.Conclusion
The results of our finite element method computational
model indicate that the average electric field induced by
TTFields therapy was above the therapeutic threshold value
of 1 V/cm in a variety of GBM tumors with different sizes,
shapes, and locations. Furthermore, adapting transducer
array layouts to specific tumor locations was highly bene-
ficial, because it led to substantial increases in the induced
field strength within the tumor and better TTFields cover-
age in the affected areas.References
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